Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

20122,954 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 380, Issue 9839, pp. 358-365

Field-Weighted Citation Impact: 134.23